Journal: Cell Systems

Article Title: Cold and hot fibrosis define clinically distinct cardiac pathologies

doi: 10.1016/j.cels.2025.101198

Figure Lengend Snippet:

Article Snippet: The following primary antibodies were used for staining. anti-LRP1 (cell culture, 1:100, ab92544, Abcam), anti-TIMP1 (cell culture, 1:50, AF980, R&D systems), anti-aSMA (cell culture & tissue sections, 1:400, A2547, Sigma), Anti-GFP (tissue sections, 1:100, ab6673, Abcam), anti-RFP (tissue sections, 1:200, 600-401-379, Rockland), Anti-Gal3 (tissue sections, 1:100, M3/38, Biolegend), anti-cardiac troponin T (cTnT) (tissue sections, 1:20, CT3, DSHB).

Techniques: Control, Recombinant, Synthesized, Sequencing, Mutagenesis, Software, Flow Cytometry, Electron Microscopy, Staining, Gene Expression

Journal: Neural plasticity

Article Title: Parthenolide Relieves Pain and Promotes M2 Microglia/Macrophage Polarization in Rat Model of Neuropathy.

doi: 10.1155/2015/676473

Figure Lengend Snippet: Figure 3: Effects of PTL on the protein levels of pronociceptive (IL-1𝛽, IL-18, iNOS, and IL-6) and antinociceptive (IL-10 and TIMP1) factors in the spinal cord 7 days after CCI. The nerve injury caused increased IL-18 (b), iNOS (d), and IL-6 (e) protein levels, but the IL-1𝛽(a) protein level was unchanged after CCI. Chronic PTL administration diminished protein levels of IL-1𝛽(a), IL-18 (b), and iNOS (d) but did not change IL-6 (e) in the dorsal part of the lumbar spinal cord 7 days after injury. The protein level of IL-10 (c) and TIMP1 (f) was unchanged in the spinal cord following CCI, but repeated administration of PTL significantly increased IL-10 (c) and TIMP 1 (f) proteins compared to those of CCI- exposed rats without PTL treatment. The data are presented as the mean ± SEM of 5–7 samples from each group. Intergroup differences were analyzed using Bonferroni’s multiple comparison test. ∗𝑃< 0.05, ∗∗𝑃< 0.01, and ∗∗∗𝑃< 0.001 indicate significant differences compared to na¨ıve rats. #𝑃< 0.05, ##𝑃< 0.01, and ###𝑃< 0.001 indicate differences between vehicle-treated and PTL-treated CCI-exposed group. N-na¨ıve, V-vehicle, and PTL-parthenolide. The immunoblots shown are representative of 5–7 individual samples.

Article Snippet: Next, the blots were incubated with the following anti-rat primary antibodies that had been diluted in a SignalBoost Immunoreaction Enhancer Kit (Calbiochem) for 24 h at 4∘C: IBA1 (ProteinTech) 1 : 1000; GFAP (Novus Biologicals) 1 : 50000; IL-1β (Abcam) 1 : 1000; IL-6 (Invitrogen) 1 : 1000; iNOS (Sigma-Aldrich) 1 : 2000; IL-18 (R&D Systems) 1 : 1000; IL-10 (Invitrogen) 1 : 2000; TIMP1 (Novus Biologicals) 1 : 2000; pp38 MAPK (Cell Signalling) 1 : 2000; p-ERK1/2 (Santa Cruz) 1 : 4000; p-NF-κB (Santa Cruz) 1 : 2000; and p-STAT3 (Cell Signaling) 1 : 2000.

Techniques: Comparison, Western Blot

Journal: Neural plasticity

Article Title: Parthenolide Relieves Pain and Promotes M2 Microglia/Macrophage Polarization in Rat Model of Neuropathy.

doi: 10.1155/2015/676473

Figure Lengend Snippet: Figure 5: Effects of LPS on the mRNA and protein level of pronociceptive (IL-1𝛽, IL-18, IL-6, and iNOS) and antinociceptive (IL-10 and TIMP1) factors in the primary rat microglial cell cultures. Samples were analyzed 24 hours after stimulation of cells with LPS. Upregulation of mRNA for IL-1𝛽(a), IL-18 (b), iNOS (c), IL-6 (d), IL-10 (e), and downregulation of mRNA for TIMP1 (f) were observed after LPS treatment. The protein level of IL-1𝛽(g), IL-18 (h), and iNOS (i) were significantly upregulated and of TIMP1 (l) was downregulated after LPS stimulation. Protein level of IL-6 and IL-10 remained unchanged after LPS administration. The qRT-PCR and Western blot data are presented as the mean ± SEM and represent the normalized averages derived from analyses of 3–10 samples for each group. Statistical analysis was performed using 𝑡test, ∗𝑃< 0.05, ∗∗𝑃< 0.01, and ∗∗∗𝑃< 0.001 indicate significant differences compared to vehicle-treated cells. LPS: lipopolysaccharide. The immunoblots shown are representative of 3–5 individual samples.

Article Snippet: Next, the blots were incubated with the following anti-rat primary antibodies that had been diluted in a SignalBoost Immunoreaction Enhancer Kit (Calbiochem) for 24 h at 4∘C: IBA1 (ProteinTech) 1 : 1000; GFAP (Novus Biologicals) 1 : 50000; IL-1β (Abcam) 1 : 1000; IL-6 (Invitrogen) 1 : 1000; iNOS (Sigma-Aldrich) 1 : 2000; IL-18 (R&D Systems) 1 : 1000; IL-10 (Invitrogen) 1 : 2000; TIMP1 (Novus Biologicals) 1 : 2000; pp38 MAPK (Cell Signalling) 1 : 2000; p-ERK1/2 (Santa Cruz) 1 : 4000; p-NF-κB (Santa Cruz) 1 : 2000; and p-STAT3 (Cell Signaling) 1 : 2000.

Techniques: Quantitative RT-PCR, Western Blot, Derivative Assay